fda compounding semaglutide warning october 2025 Wegovy HD Safety Alerts, Recalls & Warnings New project announcement: HHS‑OIG is

For laboratory and research use only.

A new randomized clinical trial just published inJAMA Psychiatrytested semaglutide (a GLP-1 agonist) in people with schizophrenia, prediabetes, and obesity who were taking antipsychotics

The GLP-1 Solution: A Complete Program to Maximize Your Weight and Fat Loss Results eBook : McDonald, Lyle, Singh, Sumi: Amazon.com.au: Kindle Store

Weight loss drugs continue to play out in the global market, with forecasts estimated at a value of US$200 billion by 2030.Leading the rise are oral GLP-1 drugs, with new obesity pills projected to push the GLP-1 market into its next chapter in 2026

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial #ERA25 In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight